Marker Therapeutics (MRKR) has released an update.
Marker Therapeutics has reported a promising start to Q1 2024 with positive developments in its APOLLO study for MT-601, showing sustained efficacy in treating lymphoma. A patient previously non-responsive to CAR T therapy achieved a complete response maintained for nine months post-treatment. The company also secured the nonproprietary name ‘neldaleucel’ for MT-601, advancing its position in the development of cancer immunotherapies.
For further insights into MRKR stock, check out TipRanks’ Stock Analysis page.
